A condition of this approval is an agreement to divest three Bemis plants located in the United Kingdom and Ireland. Combined, these plants generate approximately US$170 million of annual revenue from the sale of flexible packaging for certain healthcare products. This approval preserves Amcor’s European healthcare-packaging business which is substantially larger and participates in attractive, high-value end markets.
The process toward securing required antitrust clearances and other regulatory consents in all jurisdictions which are conditional to closing have either been completed or are progressing in line with expectations.
The transaction remains subject to regulatory approval in the United States and Brazil, and the companies are in advanced discussions with regulators in both countries. Those advanced discussions include the potential for required remedies. Inclusive of remedies required by the European Commission, collective potential remedies would represent an immaterial proportion of the total sales for the combined company and would not impact the US$180 million of net cost synergies expected to be delivered by the end of the third year following completion, Amcor says.
The transaction is expected to close in Q2 2019.